Treatment of secondary hyperparathyroidism with parathyroidectomy instead of cinacalcet: time to pick the low-hanging fruit?

[1]  I. Kamae,et al.  Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  S. Weinberger,et al.  Providing High-Value, Cost-Conscious Care: A Critical Seventh General Competency for Physicians , 2011, Annals of Internal Medicine.

[3]  G. Plosker.  Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease. , 2011, PharmacoEconomics.

[4]  A. Hayen,et al.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. , 2011, JAMA.

[5]  D. Bartsch,et al.  An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. , 2010, Surgery.

[6]  J. Wetmore,et al.  Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[7]  Jiannong Liu,et al.  Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. , 2010, Kidney international.

[8]  Herb Chen,et al.  Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. , 2009, Surgery.

[9]  J. Ornato,et al.  [ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery]. , 2009, Masui. The Japanese journal of anesthesiology.

[10]  A. Palmer,et al.  Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[11]  R. Ravasio,et al.  Analisi costo-efficacia di cinacalcet più terapia standard versus terapia standard nel trattamento dei pazienti in dialisi con iperparatiroidismo secondario , 2008 .

[12]  A. Palmer,et al.  Cost-utility analysis of cinacalcet in addition to standard of care in the UK. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  J. Ornato,et al.  ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiov , 2007, Circulation.

[14]  K. Mahaffey,et al.  Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[15]  K. Abbott,et al.  Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Martin Pitt,et al.  The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  G. Chertow,et al.  Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. , 2005, Kidney international.

[18]  B. Kestenbaum,et al.  Survival following parathyroidectomy among United States dialysis patients. , 2004, Kidney international.

[19]  Q. Duh,et al.  Parathyroidectomy for primary hyperparathyroidism in octogenarians and nonagenarians: a plea for early surgical referral. , 2003, Archives of surgery.

[20]  P. Messa,et al.  Persistent secondary hyperparathyroidism after renal transplantation. , 1998, Kidney international.

[21]  G. Pontoriero,et al.  Economic Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism in Italy , 2012, PharmacoEconomics.

[22]  Usrds.  NIH, U. . Renal Data System: Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. , 2012 .

[23]  M. Arenas,et al.  [Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?]. , 2008, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.